FEMALE SEXUALITY: MODULATION BY ESTROGEN AND ANDROGEN

女性性欲:雌激素和雄激素的调节

基本信息

  • 批准号:
    7562551
  • 负责人:
  • 金额:
    $ 3.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-05-01 至 2008-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypothesis is investigated that female sexual interest is stimulated by the neural actions of ovarian estrogens and that androgens regulate the bioavailability of these estrogens through interactions with sex hormone binding globulin (SHBG). Three projects, using a rhesus monkey model of endocrine function and behavior, investigate the hormonal basis of female sexual initiation. Project I investigates sexual initiation in females across the menstrual cycle, comparing the occurrence of female sexual initiation in a social group context during normal cycles vs cycles treated with an androgen receptor blocker (flutamide) or an estrogen receptor blocker (tamoxifen). Project II tests the novel hypothesis that SHBG regulates bioavailable estrogens and androgens through these steroids' different affinities for SHBG. This project uses a monkey model of hormonal replacement therapy for reproductively prime females after surgical removal of their ovaries and tests the hypothesis that chronic estradiol (E2) ceases to effectively stimulate female sexual interest as estrogen is sequestered by SHBG. It further investigates whether an androgen, 5a-dihydrotestosterone (DHT), with a markedly higher affinity for SHBG than estradiol, can acutely and rapidly reinstate female sexual interest by increasing free estradiol by displacing SHBG-bound estradiol. Ovariectomized females receiving chronic estradiol treatment mimicking mid follicular estradiol levels are observed for sexual initiation during chronic E2 treatment alone and following chronic E2 and an injection of DHT or E2. Concurrent administration of flutamide or tamoxifen with the estrogen or DHT will discriminate between behavioral changes resulting from the activation of neural androgen or estrogen receptors. Project III investigates whether common human hormonal replacement therapies of chronic estrogen, or chronic estrogen plus testosterone with or without concurrent progestin can reinstate female sexual interested in reproductively prime ovariectomized female monkeys. The hypothesis will be tested that chronic progestin therapy reduces or eliminates the effectiveness therapies that reinstate female sexual interest without progestin. These therapies will also be compared on their effects on neuroendocrine function. Theses studies increase our understanding of the role that ovarian steroids play in modulating female sexuality.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 研究的假设是,女性的性兴趣是由卵巢雌激素的神经行为刺激,雄激素通过与性激素结合球蛋白(SHBG)的相互作用调节这些雌激素的生物利用度。 三个项目,使用恒河猴模型的内分泌功能和行为,调查女性性启动的激素基础。项目I调查了女性在整个月经周期中的性启动,比较了在正常周期与雄激素受体阻滞剂(氟氯噻嗪)或雌激素受体阻滞剂(他莫昔芬)治疗周期中女性在社会群体背景下的性启动发生率。 项目II测试了SHBG通过这些类固醇对SHBG的不同亲和力调节生物可利用的雌激素和雄激素的新假设。 该项目使用激素替代治疗的猴子模型,用于手术切除卵巢后的生殖初期女性,并测试慢性雌二醇(E2)不再有效刺激女性性兴趣的假设,因为雌激素被SHBG隔离。 它进一步研究了雄激素,5 α-双氢睾酮(DHT),具有显着更高的亲和力比雌二醇的SHBG,是否可以通过增加游离雌二醇取代SHBG结合雌二醇急性和快速恢复女性的性兴趣。 观察接受模拟卵泡中期雌二醇水平的长期雌二醇治疗的卵巢切除女性在单独的长期E2治疗期间以及在长期E2和注射DHT或E2之后的性启动。 氟替卡松或他莫昔芬与雌激素或双氢睾酮同时给药可区分由神经雄激素或雌激素受体激活引起的行为变化。项目III研究了慢性雌激素或慢性雌激素加睾酮(伴或不伴雌激素)的常见人类激素替代疗法是否可以恢复雌性对生育初期卵巢切除雌性猴的性兴趣。该假设将被测试,慢性前列腺素治疗减少或消除的有效性疗法,恢复女性的性兴趣没有前列腺素。还将比较这些疗法对神经内分泌功能的影响。 这些研究增加了我们对卵巢类固醇在调节女性性行为中的作用的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kim Wallen其他文献

Kim Wallen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kim Wallen', 18)}}的其他基金

AMYGDALA: SEX DIFFERENCES IN BEHAVIOR, COGNITION NEUROENDOCRINE DEVELOPMENT
杏仁核:行为、认知神经内分泌发育的性别差异
  • 批准号:
    8357457
  • 财政年份:
    2011
  • 资助金额:
    $ 3.16万
  • 项目类别:
AMYGDALA: SEX DIFFERENCES IN BEHAVIOR, COGNITION NEUROENDOCRINE DEVELOPMENT
杏仁核:行为、认知神经内分泌发育的性别差异
  • 批准号:
    8172409
  • 财政年份:
    2010
  • 资助金额:
    $ 3.16万
  • 项目类别:
BEHAVIORAL DEVELOPMENT PRENATAL HORMONAL INFLUENCES
行为发展产前荷尔蒙的影响
  • 批准号:
    7958110
  • 财政年份:
    2009
  • 资助金额:
    $ 3.16万
  • 项目类别:
AMYGDALA: SEX DIFFERENCES IN BEHAVIOR, COGNITION NEUROENDOCRINE DEVELOPMENT
杏仁核:行为、认知神经内分泌发育的性别差异
  • 批准号:
    7958234
  • 财政年份:
    2009
  • 资助金额:
    $ 3.16万
  • 项目类别:
AMYGDALA: SEX DIFFERENCES IN BEHAVIOR, COGNITION NEUROENDOCRINE DEVELOPMENT
杏仁核:行为、认知神经内分泌发育的性别差异
  • 批准号:
    7715836
  • 财政年份:
    2008
  • 资助金额:
    $ 3.16万
  • 项目类别:
FEMALE SEXUALITY: MODULATION BY ESTROGEN AND ANDROGEN
女性性欲:雌激素和雄激素的调节
  • 批准号:
    7715706
  • 财政年份:
    2008
  • 资助金额:
    $ 3.16万
  • 项目类别:
BEHAVIORAL DEVELOPMENT PRENATAL HORMONAL INFLUENCES
行为发展产前荷尔蒙的影响
  • 批准号:
    7715672
  • 财政年份:
    2008
  • 资助金额:
    $ 3.16万
  • 项目类别:
BEHAVIORAL DEVELOPMENT PRENATAL HORMONAL INFLUENCES
行为发展产前荷尔蒙的影响
  • 批准号:
    7562508
  • 财政年份:
    2007
  • 资助金额:
    $ 3.16万
  • 项目类别:
Integrated Training in Psychobiology and Psychopathology
心理生物学和精神病理学综合培训
  • 批准号:
    7066801
  • 财政年份:
    2006
  • 资助金额:
    $ 3.16万
  • 项目类别:
FEMALE SEXUALITY: MODULATION BY ESTROGEN AND ANDROGEN
女性性欲:雌激素和雄激素的调节
  • 批准号:
    7349200
  • 财政年份:
    2006
  • 资助金额:
    $ 3.16万
  • 项目类别:

相似海外基金

Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
  • 批准号:
    DP230103210
  • 财政年份:
    2023
  • 资助金额:
    $ 3.16万
  • 项目类别:
    Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
  • 批准号:
    10584689
  • 财政年份:
    2023
  • 资助金额:
    $ 3.16万
  • 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
  • 批准号:
    10650956
  • 财政年份:
    2023
  • 资助金额:
    $ 3.16万
  • 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
  • 批准号:
    10488954
  • 财政年份:
    2023
  • 资助金额:
    $ 3.16万
  • 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
  • 批准号:
    10651105
  • 财政年份:
    2023
  • 资助金额:
    $ 3.16万
  • 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
  • 批准号:
    10603636
  • 财政年份:
    2023
  • 资助金额:
    $ 3.16万
  • 项目类别:
Androgen receptor function in melanoma
雄激素受体在黑色素瘤中的功能
  • 批准号:
    10416658
  • 财政年份:
    2022
  • 资助金额:
    $ 3.16万
  • 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
  • 批准号:
    10544062
  • 财政年份:
    2022
  • 资助金额:
    $ 3.16万
  • 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
  • 批准号:
    10534943
  • 财政年份:
    2022
  • 资助金额:
    $ 3.16万
  • 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
  • 批准号:
    10677989
  • 财政年份:
    2022
  • 资助金额:
    $ 3.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了